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Background: DNA methylation variability regions (MVRs) across the oestrogen receptor alpha (ESR1) gene have
been identified in peripheral blood cells from breast cancer patients and healthy individuals. In contrast to
promoter methylation, gene body methylation may be important in maintaining active transcription. This study
aimed to assess MVRs in ESR1 in breast cancer cell lines, tumour biopsies and exfoliated epithelial cells from
expressed breast milk (EBM), to determine their significance for ESR1 transcription.
Methods: DNA methylation levels in eight MVRs across ESR1 were assessed by pyrosequencing bisulphite-converted
DNA from three oestrogen receptor (ER)-positive and three ER-negative breast cancer cell lines. DNA methylation and
expression were assessed following treatment with DAC (1 μM), or DMSO (controls). ESR1 methylation levels were also
assayed in DNA from 155 invasive ductal carcinoma biopsies provided by the Breast Cancer Campaign Tissue Bank, and
validated with DNA methylation profiles from the TCGA breast tumours (n = 356 ER-pos, n = 109 ER-neg). DNA
methylation was profiled in exfoliated breast epithelial cells from EBM using the Illumina 450 K (n = 36) and
pyrosequencing in a further 53 donor samples. ESR1 mRNA levels were measured by qRT-PCR.
Results: We show that ER-positive cell lines had unmethylated ESR1 promoter regions and highly methylated
intragenic regions (median, 80.45%) while ER-negative cells had methylated promoters and lower intragenic
methylation levels (median, 38.62%). DAC treatment increased ESR1 expression in ER-negative cells, but significantly
reduced methylation and expression of ESR1 in ER-positive cells. The ESR1 promoter was unmethylated in breast
tumour biopsies with high levels of intragenic methylation, independent of ER status. However, ESR1 methylation in
the strongly ER-positive EBM DNA samples were very similar to ER-positive tumour cell lines.
Conclusion: DAC treatment inhibited ESR1 transcription in cells with an unmethylated ESR1 promoter and reduced
intragenic DNA methylation. Intragenic methylation levels correlated with ESR1 expression in homogenous cell
populations (cell lines and exfoliated primary breast epithelial cells), but not in heterogeneous tumour biopsies,
highlighting the significant differences between the in vivo tumour microenvironment and individual homogenous cell
types. These findings emphasise the need for care when choosing material for epigenetic research and highlights the
presence of aberrant intragenic methylation levels in tumour tissue.
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Breast cancer is the leading cause of cancer in women,
and its incidence continues to rise, particularly in devel-
oped countries [1]. Strong evidence exists to support the
role of aberrant epigenetic mechanisms in breast tumori-
genesis, of which the most intensively investigated are
changes in DNA methylation [2-4]. DNA methylation is
evolutionarily the oldest and perhaps best studied mech-
anism of epigenetic transcriptional regulation, whereby a
methyl group is covalently added to the 5-carbon of
cytosine bases in a cytosine-guanine dinucleotide (CpG
site). CpG sites tend to cluster into non-random CpG
islands (CGIs) around the transcription start sites (TSS)
of approximately 60% of genes. Dogma states that
methylation of the promoter region-associated CGIs
leads to conformational changes in the DNA strand and
regional chromatin [5,6], which inhibit the initiation of
the transcriptional machinery and prevent the recruitment
of RNA polymerase II. If the CGI is unmethylated, the
gene should be actively transcribed.
A recent review indicated that the differential methy-
lation of intragenic variable regions may have import-
ant implications for transcription and cell-specific
differentiation [7]. Changes in intragenic methylation
(IGM) levels may represent the consequences of the
transcriptional machinery [8], or a functionally rele-
vant mechanism that affects transcriptional efficiency
or gene stability [9-11]. It is likely that there are gene-
to-gene subtleties in such mechanisms, and function-
ally important genes in breast cancer therefore warrant
closer investigation as the transcriptional regulation of
genes during breast tumorigenesis and throughout the
disease course remains poorly understood. One such
gene, oestrogen receptor alpha (ESR1), is of crucial
importance in terms of both diagnostic and prognostic
implications in breast cancer [12-14]. A previous study
from our group indicated that regions of DNA methy-
lation variability (MVRs) exist across the ESR1 gene in
peripheral blood cells from breast cancer patients
compared to healthy matched controls [15], but the
functional implications of this variability remains
unknown.
Based on the hypothesis that IGM may play an im-
portant role in transcription [16-19], we aimed to ascer-
tain whether IGM patterns differed in human breast
cancer cells lines that were positive (n = 3) or negative
(n = 3) for ESR1 expression. We also explored the ef-
fects on the cells in terms of the methylation and tran-
scription of ESR1 after treatment with a demethylating
agent, decitabine (DAC), Furthermore, methylation
levels across the ESR1 gene were assessed in 155 sam-
ples of human breast cancer, and in 89 samples of exfo-
liated breast epithelial cells from donated expressed
breast milk (EBM) from healthy women.Methods
Cell lines
Six cell lines were obtained from stocks at the Hammer-
smith Hospital or purchased (ATCC, VA, USA). Of these,
three were confirmed as ESR1-positive (T47D, MCF7, and
BT474) and three were ESR1-negative (MDA-MB-231,
BT549, and SKBR3), verified by STR profiling. Cells were
cultured in sterile conditions at 37°C in a humidified
atmosphere with 5% carbon dioxide, and maintained in
either DMEM (Sigma-Aldrich, Poole, UK) or RPMI
(Sigma) supplemented with 10% fetal calf serum (FCS;
Sigma) and 5 ml L-glutamine. Cells were passaged when
their confluence exceeded 70%.Decitabine treatment
The effect of increasing concentrations of DAC on the six
cell lines was assessed using the MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide) dye reduc-
tion assay. Decitabine (DAC; Sigma-Aldrich) was re-
suspended in 2.2 ml 100% dimethyl sulphoxide (DMSO;
Sigma-Aldrich), and made up to 0.5, 1, 5, 10, or 20 μM
compared to growth medium (0 μM) alone as the negative
control. Assays were performed in triplicate, and the
MTT assay was performed using 20 μl CellTiter 96 Aque-
ous One Solution Cell Proliferation Assay (Promega,
Madison, WI, USA) according to the manufacturer’s
protocol. The results indicated that cell viability was pre-
served for each cell line at ≤5 μm DAC. Therefore, 1 μm
DAC was chosen for the subsequent cell culture experi-
ments to prevent DAC cytotoxicity.
Fresh aliquots of DAC and DMSO were used for each
experiment. Each cell line was cultured in 75 cm3 flasks
in 10 ml DMEM+ 10% FCS with 1 μM DAC or DMSO
for 7 d in triplicate, and at three separate time points.
After the appropriate duration of incubation, cells were
trypsinised and counted. Cell pellets were collected after
three PBS washes and centrifugation at 1,500 rpm for
5 min, and divided in half for DNA and RNA extraction.
DNA was extracted using the QIAamp® DNA Mini Kit
(Qiagen, Crawley, UK), and concentration and quality
was assessed using a Nanodrop1000 spectrophotometer
(ThermoScientific, UK). DNA was stored at −20°C until
bisulphite conversion.Methylation analyses
Bisulphite conversion changes all unmethylated cytosine
bases into uracil, therefore allowing the identification of
unconverted cytosines as those that are methylated by
pyrosequencing [20]. DNA samples were bisulphite-
converted using the EpiTect kit according to the manu-
facturer’s protocol (Qiagen). Bisulphite-treated DNA
was then desulphonated, washed and eluted prior to its
use in PCR.
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to avoid the amplification of repetitive elements, such as
long-interspersed nuclear elements (LINE) segments,
which are often present in the MVRs across ESR1 [15]. A
biotinylated tag was placed on one of the primers, and a
common biotinylated primer was used for all reactions as
described in previous reports [15,21]. The list of PCR and
sequencing primer sequences is given in Additional file 1:
Table S1. The prepromoter region assayed was found be-
tween −4839 and −3904 bp upstream of the transcription
start site (TSS), while the promoter region assayed
comprised CpG sites from the TSS to 178 bp into the
gene. Reactions took place in a thermal cycler under the
following conditions: incubation at 95°C for 10 min; an
initial 20 sec incubation at 95°C followed by 10 cycles of a
20 s incubation at 60°C (temperature decreased by 1.0°C
every cycle) and incubation at 72°C for 20 s; second round
PCR steps were performed using nested primers as fol-
lows: 30 cycles at 95°C for 20 s, 50°C for 20 s and 72°C for
20 s followed by a final incubation of 72°C for 5 min, with
the exception of MVR 7b which only required a single-
step PCR amplification. Products were assessed for quality
by agarose gel electrophoresis and stored at 4°C until
pyrosequencing.
Bisulphite-converted DNA samples were pyrosequenced
using specific sequencing primers designed with the use of
the PyroQ assay design software (Pyromark MD, Qiagen),
and assay were performed on a Pyromark MD pyrose-
quencer using standard protocols and controls. Assays
were repeated if any the inbuilt quality control measures
were flagged.
RNA isolation, cDNA synthesis and qRT-PCR assays of cell
line RNA
RNA was isolated from cell pellets using the Qiagen
RNeasy® Mini kit (Qiagen), according to the manufac-
turer’s instructions. The concentration of each RNA sam-
ple was assessed with the Nanodrop and all OD260/280
ratios were >1.8. cDNA was synthesised from 2 μg of each
RNA sample using the SuperScript™ III First Strand Syn-
thesis System for RT-PCR (Invitrogen, Carlsbad, CA,
USA). Negative controls were prepared without Super-
script™ III RT for each group of samples. All samples were
stored at −20°C prior to RT-PCR.
Each qRT-PCR analysis was performed in triplicate for
each of the duplicate experimental sets of cDNA from
the six cell lines. Each qRT-PCR run was performed in
duplicate using primers that were specific for ESR1
mRNA and for the housekeeping gene, GADPH (for-
ward, 5′-TCCCATCACCATCTTCCA-3′ and reverse,
5′-CATCACGCCACAGTTTCC-3′) [22]. The details of
primers used are given in Additional file 1: Table S2, and
assays were checked using gel electrophoresis to confirm
the expected amplicon sizes were valid. All primers were100% specific for the region of interest. The plate was
centrifuged briefly and placed in a C1000™ Thermal Cycler
(BioRad, UK). The PCR conditions were established using
the Bio-Rad CFX Manager software as follows: 95°C for
3 min denaturing step; 42 cycles of 10 s at 95°C, 10 s at
56°C and 30 s at 72°C; 10 s at 95°C and a melt curve cycle
of 5 min that ranged from 72°C to 95°C. Cycle threshold
(Ct) values were recorded at a logarithmic threshold of
103, and the relative quantitative expression of ESR1
mRNA in each sample was calculated by the -ΔΔCt
conversion.
Breast tumour samples
Power calculations based on the observed differences in
cell lines suggested that group sample sizes of n = 45 would
be sufficient to reach >90% power at alpha = 0.01 to detect
the maximum difference observed (p6), and >80% power
at alpha = 0.05 to detect a significant difference of >40%
methylation (observed at other sites across ESR1). We re-
ceived samples from the Breast Cancer Campaign Tissue
Bank, comprising 10 formalin-fixed paraformaldehyde
slides per tumour for 135 tumours (45 ER-negative tu-
mours samples, 45 ER-positive grade 2 tumours and 45
ER-positive grade 3 tumours, as defined from histopatho-
logical review by MEB). Furthermore, we received 20
samples of fresh frozen (FF) tumours matched to FFPE
samples for quality control purposes. This study was
approved by the Ethics Committee of the Breast Cancer
Campaign Tissue Bank (Approval no. BCC-TB00001). All
H&E stained slides were reviewed by a pathologist to
define the percentage of tumour with a minimum cut-off
of >70%.
Slides were dewaxed for 10 min in Histoclear, followed
by 10 min in 100% ethanol and another 10 min in fresh
100% ethanol. Slides were prepared with Levi buffer using
standard techniques, and DNA was extracted using the
phenol:chloroform technique. DNA concentrations and
quality were assessed by the Nanodrop. Bisulphite conver-
sions and pyrosequencing analyses were performed as
described above. For the DNA extracted from FFPE slides,
different primers had to be described with amplicons
of <120 bp owing to the relative fragmentation of the
DNA after formalin treatment, as DNA quality was poorer
in these 135 samples (Additional file 1: Table S4).
Slides were stained immunohistochemically with anti-
bodies against Ki67 according to standard protocols to as-
sess the rate of cell proliferation within tumour sections.
Briefly, 2-μm-thick sections from formalin-fixed, paraffin
embedded tissue blocks were prepared, deparaffinised and
rehydrated. Immunohistochemical staining and detection
was performed using an automated Leica Bond 3 machine
according to the manufacturer’s protocol. Antibodies
raised against Ki67 (Leica, Cat No: NCL-L-Ki67-MM1,
1:100) and ER (Leica, Cat No: NCL-ER-6 F11, 1:500) were
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mer refine detection kit. Tonsil sections were used as a
positive control for Ki67 staining and breast tissue was
used for ER staining. Negative controls were processed in
the same manner but with the substitution of PBS for the
primary antibody. All sections were examined by light mi-
croscopy to assess the presence and scoring of expression.
The percentage of tumour cells with nuclear expression of
Ki67 was estimated. The Allred scoring system was used
to assess ER staining.
Methylation data in BCC Tissue Bank tumour biopsies
was validated using the TCGA breast tumour for which
450 K Illumina Infinium Beadchip Array data was publi-
cally available (n = 365 ER-positive tumours, n = 109 ER-
negative tumours). Data was extracted using R software
and logistic regression analysis was performed to assess
the relationship between ER-status and methylation
beta-values at each ESR1 CpG locus, with histology as
an independent variable. The Wilcoxon signed rank sum
test was performed with false discovery rate correction
as the data was non-parametric.
Extraction and processing of breast epithelial cell samples
from expressed breast milk
Ethics approval for this part of the study was obtained
from the Hammersmith Hospital Human Imperial NHS
Tissue Bank access committee (reference R13020). Cells
were pelleted from frozen 20-ml samples of expressed
breast milk in a series of centrifugation and wash steps,
and analysed using flow cytometry with a FITC labelled
antibody against epithelial membrane antigen (EMA;
CD227, Sigma Aldrich; n = 60) and a Cyp5.5-labelled anti-
body against intracellular ESR1 (Sigma Aldrich; n = 6),
according to standard techniques using a FACScalibur
flow cytometer (BD Biosciences). DNA was extracted
using a phenol:chloroform technique, with duplicate phe-
nol and chloroform steps to optimise yields and reduce
phenol contamination, respectively. DNA was bisulphite
converted (500 ng) using the EZ-96 Methylation-Gold™
kit (Zymo) and samples from 36 donors were used for
hybridisation onto the Infinium HumanMethylation 450
BeadChip array, using the Illumina Infinium HD
methylation protocol (conducted by UCL Genomics).
The methylation scores from samples on all three chips
were processed using standard quality control mea-
sures, and normalised (colour correction) and batch ad-
justed using COMBAT, resulting in beta methylation
values according to the fluorescent intensity ratio that
ranged from 0 (unmethylated) to 1 (completely methyl-
ated). R was also used to analyse the probes related to
ESR1. Pyrosequencing was subsequently performed for
the ESR1 regions described above on 250 ng bisulphite
converted DNA samples (n = 53) to validate the ESR1
regional methylation.RNA was found to be highly fragmented from frozen
milk samples according to assessment by the Bioanalyser
2100 (Agilent Technologies, Santa Clara, CA, USA)
using standard techniques, and was unsuitable for fur-
ther use. A small number of fresh breast milk samples
were collected and high quality RNA, according to the
results of the Bioanalyser 2100 (RIN score >7), was
obtained from 11 samples using a standard Trizol tech-
nique. Furthermore, the OD260/280 was >1.8 for all 11
samples. cDNA was prepared and qPCR assays for ESR1
were performed according to the techniques and primers
described above for the cell line analysis. EBM samples
were normalised against MCF7, and MDA-MB-231
RNA was used as the negative control, along with a
negative reverse transcriptase sample.
Statistical analysis
All experiments were performed in triplicate unless
otherwise stated. The mean ± standard deviation (SD)
was calculated from each triplicate repeat of the pyrose-
quencing and qRT-PCR experiments. The mean ± SD
were calculated after each replicate, and the standard
error of the mean (SEx) was then calculated. Parametric
data, such as the methylation levels in cells incubated
with DMSO and DAC or DMSO alone, were compared
using paired t-tests. Non-parametric data, including
average methylation levels across the gene body, were
compared using unpaired Wilcoxon signed rank sum
tests. All statistical tests were two-sided and performed
using Microsoft Excel (Microsoft, USA). To validate the
expression changes of ESR1 after DAC treatment, two
publically available expression datasets were mined for
data regarding DAC treatment of two breast cancer cell
lines used in this current study (gse10613 and gse13733)
[23,24]. The software programmes, R v2.15 and Micro-
soft Excel, were used to analyse all data.
Results
Differences in intragenic methylation (IGM) patterns
across ESR1 between ER-pos and ER-neg cell lines
In total, nine distinct regions across the pre-promoter,
promoter and intragenic regions of the ESR1 gene were
assayed by pyrosequencing (Figure 1A). Methylation levels
at two and three adjacent CpG loci were averaged for each
site, as shown in brackets in the x-axis of Figure 1B, and
two distinct patterns were observed (Figure 1B). Pre-
promoter methylation levels in ER-positive and ER-negative
cells were 79.1% vs. 22.5%, promoter methylation levels
were 4.3% vs. 19.5%, and average IGM levels were 80.5% vs.
38.6%, respectively.
ER-positive cells had particularly low levels of methyla-
tion at the transcription start site, as would be expected in
a transcriptionally active gene. This region of hypomethy-
lation extended into the first intron, with methylation
Figure 1 Intragenic DNA methylation in the ESR1 gene. A) Schematic showing the position of pyrosequencing assays across the ESR1 gene.
B) The DNA methylation levels across the ESR1 gene in three ER-pos cell lines (blue) and three ER-neg cell lines (red). Data was collected in
triplicate in each cell line at each locus, and the standard error of the mean was then calculated (error bars); *p < 0.05, Bonferroni corrected t-test.
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(Figure 1B), 1,627 nucleotides downstream from the TSS.
All six cell lines showed increasing methylation levels to-
wards the 3’UTR, regardless of ER expression status.In vitro ESR1 methylation changes after DAC treatment
After 1 week of treatment with 1 μM DAC, both the
ER-negative and ER-positive sets of cell lines showed a
consistent decrease in methylation across the ESR1 gene
(P < 0.05; (Figure 2A, B).
The average promoter methylation level after DAC treat-
ment was 3.7% and 5.5% in ER-positive and ER-negative
cell lines, respectively, compared to the average post-DAC
IGM levels which reduced from 80% to 50% (ER-positive)
and 38% down to 31% (ER-negative) (Figure 2A). ER-
positive cells had persistently low levels of methylation at
the CpG sites in the region of the transcription start site,
which extended into the first intron (Figure 2B).
Expression levels of ESR1 mRNA
We assayed the level of ESR1 mRNA in all six human
breast cancer cell lines in DAC-treated and control cells
using RT-PCR. In ER-negative cells, 1 μM DAC increased
ESR1 mRNA expression significantly (MDA-MB-231 cells:20-fold; p = 0.003; BT549: 3-fold, p = 0.037; SKBR3: 35-fold,
p = 0.023; Figure 2C, Additional file 2: Figure S2). In ER-
positive cells, treatment with DAC decreased expression
ranging from 0.31 in MCF7 cells (p = 0.023) to 0.42 in
BT474 cells (p = 0.0034) and 0.37 in T47D (p = 4.8 × 10−6;
Figure 2D).
We used previously published data to replicate this
result using gene expression profiles of MCF7 and MDA-
MB-231 cells treated with DAC (gse10613 and gse13733)
[23,24]. Expression profiles were categorised into four
quartiles, with the highest quartile representing the genes
that had the top 25% expression levels prior to DAC treat-
ment. The genes that mirrored the behaviour of ESR1
after DAC treatment in MCF7 cells in our in vitro study,
could then be identified (Additional file 2: Figure S1, 4th
quartile genes with reduced expression after DAC treat-
ment, n = 40). This confirms that ESR1 was one of the most
downregulated genes in MCF7 following DAC treatment,
and upregulated in MDA-MB-231 s, but also identifies
other genes, including several histone proteins, that are
similarly downregulated upon DAC treatment.
ESR1 IGM levels in DNA from breast tumour biopsies
We received 155 breast tumour samples from the Breast
Cancer Campaign Tissue Bank. These came in two
020
40
60
80
100
DMSO
DAC
M
et
hy
la
tio
n 
(%
)
* * * *
*
*
*
B
0
20
40
60
80
100
DMSO
DAC
M
et
hy
la
tio
n 
(%
)
*
*
*
*
A
MDA-MB-231 BT549 SKBR3
p = 0.0030
p = 0.0233
p = 0.0038
F
ol
d 
ch
an
ge
T47D BT474 MCF7
p = 0.0034 p = 0.0227 p = 4.8x10-6 
F
ol
d 
ch
an
ge
C D
p1  Promoter               p2                          p3                         p4                           p5             
Figure 2 The effect of decitabine on DNA methylation and expression in breast cancer cell lines. A) Composite graphs showing the DNA
methylation levels across the ESR1 gene in three ER-neg cell lines treated with DAC (yellow) compared to DMSO-treated controls (red). Data was
collected in triplicate in each cell line at each locus, and the standard error of the mean was then calculated (error bars); *p < 0.05, Bonferroni
corrected t-test. B) DNA methylation across the ESR1 gene in ER-pos cell lines treated with DAC (purple) compared to untreated (blue). C, D) qRT-PCR
gene expression in individual cell lines treated with DAC (ER-neg = yellow, ER-pos = purple) compared to DMSO-treated controls (ER-neg = red;
ER-pos = blue). Expression increased significantly in ER-neg cell lines, but was significantly reduced in all three ER-pos cell lines (p < 0.05).
Shenker et al. BMC Cancer  (2015) 15:337 Page 6 of 12separate sets: 20 fresh frozen tumour blocks with FFPE
slides from the same tumours (ER-positive = 10; ER-
negative = 10) and 135 tumours that were provided as
formalin-fixed paraffin embedded slides (FFPE; n = 45
ER-neg, n = 45 ER-positive grade 2, n = 45 ER-positive
grade 3; 10 slides from each tumour, 3-μm sections).
New primers were designed to accommodate shorter
fragments in FFPE derived DNA (Additional file 1:
Table S2), and tested in the 20 fresh frozen samples vs.
their matched FFPE DNA samples. There was a rela-
tively high correlation between the results gained from
the two methods of tissue preparation (r2 = 0.77, data
not shown), but there was significantly more variation
in the FFPE compared to the FF tumours.
The promoter region of most tumours was unmethy-
lated regardless of ER status, with average methylationlevels of <5% in both ER-positive and ER-negative biop-
sies. Furthermore, the intragenic pattern of methylation
did not show as much variability across the entire gene
as was observed in cell lines. The only region that was
significantly different between ER-positive and ER-
negative tumours were the two CpG sites 7,837 bp from
the transcription start site in the first intron (MVR p3;
p = 0.01). However, in contrast to the cell lines, the
methylation levels at this region were higher in the ER-
negative FF tumours (82.1%) compared to ER positive
tumours (57.3%; Figure 3A), which was not predicted
by the in vitro studies. This site was not differentially
methylated between grade 2 and 3 ER-positive tumours,
although grade 2 tumours were slightly higher methyl-
ated at this region than grade 3 (62.1% vs. 51.5%;
p > 0.05; Figure 3B).
Figure 3 ESR1 intragenic DNA methylation in breast tumour DNA. (A) Pyrosequencing based methylation data across the ESR1 gene in fresh
frozen (FF) human breast tumour samples (n = 10 ER-negative, n = 10 ER-positive [n = 5 grade 2 vs. grade 3]). At regions p2 and p3 (approx.
2–8 kb downstream of the TSS), methylation levels were variable and significantly more methylated in ER-negative tumours, *p < 0.05. (B) In
ER-positive FF tumours, methylation levels were very similar between grades. (C) 450 K Beadchip methylation analysis of ESR1 methylation from
TCGA breast tumours (blue line = ER-positive tumours, n = 365; red line = ER-negative tumours, n = 109). The methylation pattern is very similar to
the data shown from breast tissue biopsy material shown in (A), with the only differences appearing within the first intron (equivalent to regions
p2 and p3 of the pyrosequenced assays in (A), Wilcoxon rank sum test, *p < 1.0 x 10−7.
Table 1 Ki67 scores of stained tumour sections
Ki67 score Mean (%) t-test MVR p3 region Mean (%) t-test
ER-pos 10.00 0.0004 ER-pos 57.3 0.01
ER-neg 68.11 ER-neg 82.1
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lines and tumour data may relate to cell proliferation rates,
which also correlate with intragenic DNA methylation
[25]. An analysis of cell proliferation was performed by
staining human cancer tumour sections (n = 45 ER-pos,
n = 45 ER neg) with an antibody against Ki67, which identi-
fies the degree of cell proliferation. As expected, ER-
negative tumours had significantly higher levels of Ki67
staining, and therefore higher proliferation, than ER-
positive tumours (Table 1). The higher number of cells that
are actively proliferating (i.e., during the S phase of the cell
cycle; data not shown), may therefore, have higher IGM
levels, and provide an explanation for the higher levels of
IGM observed in the ER-negative tumours. The degree of
Ki67 staining was positively correlated with increased
methylation levels at p2, p3 and p7, which were also theregions that were differentially methylated between ER-
negative and ER-positive breast cancers (data not shown).
Data from the TCGA dataset showed a markedly similar
pattern of methylation across ESR1 to those of the BCC
Tissue Bank tumour samples described above (Figure 3C).
In particular, ER-negative tumours showed significantly
higher beta methylation values than ER-positive tumours
at the three cg loci located within the first intron
(cg04063345, cg15626350, cg00601836; p < 1.0 × 10−7 for
Shenker et al. BMC Cancer  (2015) 15:337 Page 8 of 12all), which were in the same region as the p2 MVR assayed
by pyrosequencing.
Methylation levels in ESR1 in breast epithelial cells from
EBM samples
Initial flow cytometry studies indicated that the median
percentage of epithelial cells within the cell pellet from
expressed breast milk was 97.8% (n = 60; IQR, 95.3%-
99.4%; Figure 4A). The proportion of stem cells was less
than 1% (CD042 antibody staining, data not shown).
ESR1 expression has not been characterised previously
in breast epithelial cells from human expressed breast
milk. Flow cytometric analyses in a small number of EBM
samples (n = 6) was conducted to assess the presence ofp1 
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Figure 4 Intragenic DNA methylation in ESR1 in exfoliated breast epithelia
epithelial membrane antigen (EMA; median positive staining, 97.8%; 95.3%-
n = 6). (B) qRT-PCR analysis of 11 EBM epithelial cell RNA samples showing
ER-neg MDA-MB-231 cell lines, (range 2.2- 19-fold higher). (C) Methylation
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cells was 90.5% (IQR, 84.4%-93.3%; Figure 4A). ESR1 ex-
pression was confirmed by qRT-PCR assays for ESR1
mRNA expression in 11 samples of freshly expressed
breast milk and was expressed ~10-fold higher than
MCF7 (Figure 4B).
We profiled DNA methylation in 36 individuals using
the Illumina Infinium HumanMethylation 450 BeadChip
and all samples passed the quality control procedures.
Data from the ESR1-associated 450 K probes was ex-
tracted and showed low levels of promoter methylation
(Figure 4C). Pyrosequencing of a separate set of bisulphite
converted DNA samples (n = 53) validated the 450 K
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l cells from expressed breast milk (EBM). (A) Flow cytometry of
99.4%; n = 60) and intracellular ESR1 (median, 90.5%; IQR, 84.4%-93.3%;
high levels of ESR1 expression normalised against ER-pos MCF7 and
values from 450 K analysis of 36 DNA samples extracted from breast
se of ER-positive cancer cell lines, and regions of variability were found
els using pyrosequencing in a separate set of 53 EBM samples
0 K analysis of EBM samples and of ER-pos cancer cell lines
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between samples as evidenced by the wide error bars in
both the 450 K data and at the region analogous to p2 in
the pyrosequencing assays (Figure 4C, D). IGM levels
remained high at most regions assayed along the ESR1
gene, in a pattern that was very similar to that shown for
ER-positive tumour cell lines (Figures 1B and 4C, D). Very
high levels of ESR1 mRNA expression were found in all
11 samples, however, we found no significant correlation
with the variable methylation in this small subset of sam-
ples (r2 = 0.0082).
Discussion
This study identified marked and reproducible differences
in the pattern of IGM across ESR1 in vitro in ER-positive
compared to ER-negative cell lines, which was supported
by similar methylation patterns in the strongly ER-positive
breast epithelial cells from breast milk samples. Promoter
regions were uniformly methylated in ER-negative cell
lines, and unmethylated in ER-positive cells. As predicted,
demethylation with DAC treatment increased the tran-
scription of ESR1 in all three ER-negative cell lines, but
the most surprising finding from this study was that DAC
resulted in decreased levels of expression in ER-positive
cell lines, via a mechanism independent from promoter
methylation. Of note, the patterns of promoter and IGM
established in tumour cell lines and a homogenous popu-
lation of breast epithelial cells from EBM samples were
highly similar, but differed markedly from those generated
from two sources of ER-positive or ER-negative tumour
biopsy samples (BCC Tissue Bank and the TCGA data-
base). These observations are likely to reflect various ca-
veats, including cell type heterogeneity and the tissue
microenvironment, which results in a mixed epigenetic
signal in tissue samples. This finding was in contrast to
the artificial nature of cell lines grown on plastic in the
presence of high concentrations of growth factors and has
important implications on the choice of tissue for epigen-
etic analyses.
The principal focus to date of the transcriptional effects
of DNA methylation has been on promoter-associated
CpG islands. The results of this current study were in ac-
cordance with recent findings by Yang et al., which indi-
cated that DAC treatment reduced the expression levels
of overexpressed genes [26]. The functional mechanism
by which IGM exerts a transcriptional effect remains un-
known, but the transcriptional changes observed for ESR1
in ER-positive cells may represent a therapeutic target.
With the advent of array techniques that examine greater
proportions of the genome, including high-density micro-
arrays and next generation sequencing based DNA methy-
lation analyses, the functional roles of IGM are becoming
more apparent [27] and are linked to gene expression
[17,18,28]. IGM levels have been shown to changemarkedly during carcinogenesis [27], but in the absence of
precise roles in the normal state, the effects of disrupted
IGM levels in aberrant cells cannot be predicted or quan-
tified. Several mechanisms by which IGM may be func-
tionally important have been proposed, including the
prevention of transcription from alternative start sites in
the gene body, chromatin regulation, the inhibition of
transposable elements, and the control of alternative
splicing [29,30]. Furthermore, high IGM levels may pre-
vent the transcription of non-coding RNA in the antisense
direction, although this finding was not supported by the
results of this current study. Moreover, the methylation of
intragenic transposable elements may affect transcription
efficiency by impeding RNA polymerase II along the gene
body [31], although recent evidence suggests that intra-
genic DNA methylation represents a by-product of the
chromatin assemblies related to transcription, and has no
direct impact on transcription efficiency [8].
DAC is currently used as a clinical treatment for myelo-
dysplastic syndrome and acute myeloid leukemia [32].
DAC is incorporated into double-stranded DNA during
cell replication, and therefore more rapidly dividing cells
might show greater levels of demethylation. The ER-
positive breast cancer cell lines in this study were passaged
more frequently than ER-negative ones, and all cell lines
were cultured in media that contained oestrogen, fuelling a
higher rate of replication in the ER-positive cells. A link be-
tween DNA methylation and proliferation has previously
been proposed by our group and others [19,33]. Aran et al.
observed that proliferating cells and tissues tended to have
higher levels of IGM [19]. This observation was corrobo-
rated by our Ki67 and methylation data in tumour biopsies
where the ER-negative tumours had a higher proportion of
proliferating cells than the ER positive tumours (Table 1).
This leads us to hypothesise that intragenic methylation
levels may be influenced by the cell proliferation rate. In
terms of the DNA from tumours biopsies, ER-negative tu-
mours had a much faster rate of cell proliferation, as indi-
cated by the significantly higher levels of staining with
Ki67 compared to ER-positive cells (Table 1). It is likely
that the higher levels of IGM observed in ER-negative
tumours were influenced by the higher levels of cell prolif-
eration in these tumours. Velicescu et al. noted that serum
starvation stalls cells at the G0/G1 phase of the cell cycle,
preventing cell division and that DNA methyltransferases
were predominantly expressed during the S phase [34].
Active demethylation of promoter regions is known to be
initiated by the same enzymes that induce methylation
(DNMT3A and 3B) [35,36], but is a long and energy
expensive process [37]. To establish if cell proliferation
does actively affect IGM levels, and the subsequent effects
on transcription, larger studies that investigate different
cell lines and clinical samples with a genome-wide micro-
array approach may be required.
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changes with the loss and redistribution of methylation.
During neoplastic change, the CGI-associated promoter
regions of multiple genes across the genome become fo-
cally hypermethylated [3,38,39], which may occur concur-
rently with genome-wide hypomethylation in tumour cells
from a variety of cancers, including breast cancer [40,41].
These IGM changes may follow a distinct order during
carcinogenesis and provide biomarkers of breast cancer
risk in healthy women [42,43], as has already been pro-
posed in ovarian cancer [44]. However, the pathological
mechanisms and implications of genome-wide demethyla-
tion are not understood, but may result in the reactivation
of repetitive elements that are usually hypermethylated,
with consequent genomic instability [45].
The observed intragenic ESR1 methylation in epithelial
cells extracted from human breast milk confirmed the
in vitro cell line findings of high levels of IGM in ER-
positive tumour cell lines, and low levels of promoter
methylation. This suggested that if a homogenous cell type
is investigated, the epigenetic profile is also more
homogenous compared to the tumour biopsy material,
where the cell-specific signatures create a mixed signal
[46]. From the limited number of samples of RNA available
from EBM (n = 11), no correlation was found between the
highly variable methylated region at p2 in ESR1 and ESR1
expression, however, further studies in a larger number of
samples will be required to investigate such associations.
Of note, this is the first study to show the feasibility of
using DNA extracted from cells in EBM for 450 K DNA
methylation analyses. All 36 samples passed the quality
control procedures, with a relatively low level of excluded
probes. Although the DNA from such frozen milk sam-
ples is relatively fragmented (data not shown), sufficient
quality is retained to enable both array and PCR-based
assays to be performed. Given that these cells are in a
highly proliferative state during lactation [47], and repre-
sent the most oestrogen responsive breast epithelial cell
type, it will be important to collect and characterise fur-
ther samples of these cells in the future to gain a greater
understanding of the normal biology of ductal epithelial
cells, and how their epigenetic status differs from cancer
cells [48]. They also represent an important resource in
which the impact of environmental and intrinsic cancer
risk factors can be assessed.
Limitations
This study had several limitations. Firstly, we have not
investigated the effect of passive demethylation via decita-
bine on distant enhancers or the many alternate pro-
moters of ESR1. Secondly, the results from breast tumour
biopsies could have been confounded by the presence of
5’hydroxymethylation, which is present in primary tissue
but not in in vitro cultured cell lines (and high passagenumber cell lines in particular). Future studies that use
novel techniques such as oxidative bisulphite sequencing
for the detection of this epigenetic mark will be needed to
assess this. Thirdly, the quality of DNA extracted from
FFPE tumour sections was relatively poor compared to
that of fresh frozen samples, leading to higher technical
variation which may have further confounded the analysis.
The technical variation in gene expression may have been
reduced by using alternative control genes to GAPDH [49].
Finally, the number of samples of epithelial cells from
EBM was relatively small, particularly for freshly expressed
samples from which it was possible to extract RNA for fur-
ther assays and larger studies are warranted. In accordance
with most previous reports, this study demonstrated a cor-
relation between methylation and expression levels. While
it is possible to remove methylation with decitabine and
show the reciprocal changes in expression, we have not
shown the reverse of adding intragenic methylation to a
gene and showing a reciprocal increase in expression. Only
now, with advances in the use of CRISPR technology, is
there promise that such an experiment might be possible,
and future investigations will examine whether this tech-
nique can work reliably for DNA methylation studies [50].
Conclusions
Numerous studies that have investigated demethylating
agents have shown that genes can be reactivated by the de-
methylation of promoter-associated CGIs. However, the re-
pression of gene transcription by demethylation is a more
recent discovery. In this study, the reduction of ESR1 tran-
scription after DAC treatment in ER-positive cells was in-
vestigated further in the search for functional insights into
IGM. This study adds to our understanding of the methy-
lation status of intragenic CpG sites, and may provide a
mechanism for the down-regulation of ESR1 expression.Additional files
Additional file 1: Table S1. Primer sets for nested, semi-nested and
single round PCR, in addition to sequencing primers for pyrosequencing.
The chromosomal coordinates denote the CpG sites on chromosome 6
analysed by pyrosequencing. Some loci were amplified using two sets of
primers to avoid repetitive elements. Table S2. Primers for RT-PCR assays.
Table S3. RT-PCR primers designed to amplify MVR regions of ESR1.
Table S4. Additional primers designed to amplify regions of interest
across ESR1 in human biopsy material.
Additional file 2: Figure S1. The heatmap shows the relative protein
expression of very highly expressed genes in MCF7 cells (n = 40
genes) that are downregulated after DAC treatment, compared to
DAC-treated MDA-MB-231 cells from two publically available datasets
(gse10613 and gse13733). Pink indicates upregulation, while blue
indicates downregulation. The changes in ESR1 expression levels are
in accordance with the findings from our current in vitro studies.
Figure S2. Average delta-CT values for each cell line (control vs.
DAC-treated), which demonstrates that DAC treatment caused
significant increases in expression in ER-neg cell lines (SKBR3, BT549,
and MDA-MB-231).
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